[Chemotherapy using gemcitabine hydrochloride for malignant lymphoma]

Area of Science:

• Oncology
• Pharmacology

Context:

• Malignant lymphomas are a group of cancers affecting the lymphatic system.
• Relapsed and refractory lymphomas present significant treatment challenges.

Purpose:

• To summarize the efficacy and safety of gemcitabine in treating malignant lymphoma.
• To review clinical evidence supporting gemcitabine's role in monotherapy and combination regimens.

Summary:

• Gemcitabine, a deoxycytidine antagonist, demonstrates significant response rates in clinical studies for peripheral T-cell and cutaneous T-cell lymphomas.
• The GDP regimen (gemcitabine, dexamethasone, cisplatin) shows efficacy in relapsed/refractory Hodgkin and non-Hodgkin lymphomas, comparable to current salvage therapies.
• The GDP regimen exhibits a favorable safety profile and supports autologous transplantation, indicating potential as induction chemotherapy.

Impact:

• Gemcitabine offers a valuable therapeutic option for patients with relapsed or refractory malignant lymphomas.
• The GDP regimen provides an effective and safe salvage chemotherapy choice, potentially improving outcomes before autologous stem cell transplantation.